Rituximab for Serious Aplastic Anemia With Platelet Transfusion Refractoriness

Launched by INSTITUTE OF HEMATOLOGY & BLOOD DISEASES HOSPITAL, CHINA · Feb 3, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the use of rituximab, a medication, for patients with severe aplastic anemia (SAA) who have trouble receiving effective platelet transfusions, a condition known as platelet transfusion refractoriness (PTR). Patients with SAA often need frequent platelet transfusions, and those with PTR may not respond well to these transfusions, leading to increased bleeding, longer hospital stays, and higher treatment costs. The goal of this study is to see if rituximab can provide a safe and effective treatment option that helps these patients reduce their reliance on transfusions.

To be eligible for this trial, participants must be at least 18 years old and have a confirmed diagnosis of severe aplastic anemia with PTR. However, some people cannot participate, such as those who are allergic to rituximab, have severe infections, or are pregnant. If you join the study, you will receive the medication and be closely monitored by the research team. This trial is currently recruiting participants, so if you or a loved one fits the criteria and is interested, it could be a chance to explore a new treatment option.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Initial diagnosed SAA with PTR
• • Age\>18 years old, regardless of gender
• • Initial diagnosed SAA with PTR
• • Age\>18 years old, regardless of gender
• Exclusion Criteria:
• • Allergy to rituximab
• • Severe active infection
• • Hypogammaglobulinemia
• • Pregnant and lactating women
• • Heart failure (NYHA classification IV)
• • Individuals with epilepsy, dementia, and other mental disorders that require medication treatment who cannot understand or follow the research protocol
• • Chronic infections or other chronic diseases that may be risk to the experiment
• • The researchers believe that it is not suitable for participants